Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
515actual
Sites
108
Countries
Argentina, Australia, Bulgaria +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-02-28 | actual | When the study began enrolling |
| Primary completion | 2025-08-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-08 | actual | The whole study's end, after follow-up |
| First posted | 2019-02-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Open-Angle Glaucoma
- Ocular Hypertension
Intervention
- Drug: Bimatoprost (SR)
Primary outcomes
what the primary-completion date above is the date OFRetreatment or rescue administered for IOP
measured Up to 48 months
Number of patients experiencing a treatment emergent adverse event
measured Baseline up to 48 months
Publications
- PMID 39985740 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed